文献速递瓣膜外科

微创与常规主动脉瓣置换联合快速释放生物瓣的比较

Minimally Invasive vs Conventional Aortic Valve Replacement With Rapid-Deployment Bioprostheses.
PubMed 文献 · Ann Thorac Surg · 2020-10-09

这项意大利多中心回顾性研究比较了全胸骨切开与迷你胸骨切开行快速释放生物瓣主动脉瓣置换的早期和中期临床及血流动力学结果。结论认为快速释放生物瓣使微创主动脉瓣置换可行,且结果与常规手术相似。

要点

  • 迷你胸骨切开与全胸骨切开行快速释放生物瓣主动脉瓣置换的早期和中期结果相似。
  • 术后平均跨瓣压差和患者-瓣膜不匹配发生率两组相似。

核心结论

  • 快速释放生物瓣允许行微创主动脉瓣置换,手术时间及临床和血流动力学结果与常规手术相似。

研究设计与样本

  • 多中心回顾性研究,分析意大利快速释放生物瓣主动脉瓣置换注册登记(INTU-ITA)数据,共1057例患者,分为全胸骨切开组(435例,41.2%)和迷你胸骨切开组(622例,58.8%),采用倾向评分加权分析。

主要发现

  • 体外循环时间在全胸骨切开组为78.5分钟,迷你胸骨切开组为83分钟(P = .414)。
  • 总体术中并发症发生率为3.8%(40例),器械成功率为95.9%(1014例),组间无显著差异。
  • 1年、3年和5年生存率在全胸骨切开组分别为94.1%、98.1%、88.5%,迷你胸骨切开组分别为91.8%、85.2%、84.8%(P = .412)。
  • 术后中位平均跨瓣压差在全胸骨切开组为10.0 mm Hg,迷你胸骨切开组为11.0 mm Hg(P = .170);患者-瓣膜不匹配发生率分别为7%和6.4%(P = .647)。

临床怎么用

  • 对于适合行快速释放生物瓣主动脉瓣置换的患者,可考虑将微创入路作为首选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this multicenter retrospective study was to compare early and midterm clinical and hemodynamic results of aortic valve replacement with rapid-deployment bioprostheses performed through conventional full-sternotomy vs mini-sternotomy. METHODS: Data from the Italian multicenter registry of aortic valve replacement with rapid-deployment bioprostheses (INTU-ITA registry) were analyzed. Patients were divided into 2 groups: full sternotomy (FS) and ministernotomy (MS). Primary endpoint was the comparison of early and midterm mortality. Secondary endpoints were: comparison of intraoperative variables, complications, and hemodynamic performance. A propensity score weighting approach was used for data analysis. RESULTS: A total of 1057 patients were analyzed: 435 (41.2%) and 622 (58.8%) in group FS and MS, respectively. Thirty-day mortality was 1.6% and 0.6% in FS and MS groups, respectively (P = .074). cardiopulmonary bypass time was 78.5 minutes and 83 minutes in FS and MS groups, respectively (P = .414). In the overall cohort, the incidence of intraoperative complications and of device success was 3.8% (40 patients) and 95.9% (1014 patients), respectively, with no significant differences between groups. Survival at 1, 3, and 5 years was 94.1%, 98.1%, 88.5% and 91.8%, 85.2%, and 84.8% in FS and MS groups, respectively (P = .412). The 2 groups showed similar postoperative gradients (median mean gradient, FS: 10.0 mm Hg, MS: 11.0 mm Hg; P = .170) and also similar incidence of patient-prosthesis mismatch (FS: 7%, MS: 6.4%, P = .647). CONCLUSIONS: According to our data, rapid-deployment bioprostheses allow the performance of minimally invasive aortic valve replacement with similar surgical times and similar clinical and hemodynamic outcomes to conventional surgery and should be considered the first choice in these procedures.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. D'Onofrio A, Tessari C, Lorenzoni G, et al. Minimally Invasive vs Conventional Aortic Valve Replacement With Rapid-Deployment Bioprostheses. Ann Thorac Surg. 2020. PMID: 33039363. doi:10.1016/j.athoracsur.2020.06.150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。